key: cord-1024295-wrzzl9aw authors: Campos Pedrosa, Lucia Fatima; Barros, Acsa Nara A.B.; Leite-Lais, Lucia title: Nutritional risk of vitamin D, vitamin C, zinc, and selenium deficiency on risk and clinical outcomes of COVID-19: a narrative review date: 2021-11-06 journal: Clin Nutr ESPEN DOI: 10.1016/j.clnesp.2021.11.003 sha: 209de8517176cc9344cc55c6427b2f9fcf26026d doc_id: 1024295 cord_uid: wrzzl9aw The pathogenicity of the current coronavirus disease (COVID-19) shows postulates that optimal status of essential nutrients is crucial in supporting both the early viraemic and later hyperinflammatory phases of COVID-19. Micronutrients such as vitamin C, D, zinc, and selenium play roles in antioxidant, anti-inflammatory, antithrombotic, antiviral, and immuno-modulatory functions and are useful in both innate and adaptive immunity. The purpose of this review is to provide a high-level summary of evidence on clinical outcomes associated with nutritional risk of these micronutrients observed in patients with COVID-19. A literature search was performed on PubMed and Google Scholar to obtain findings of cross-sectional and experimental studies in humans. The search resulted in a total of 1212 reports including all nutrients, but only 85 were included according to the eligibility criteria. Despite the diversity of studies and the lack of randomized clinical trials and prospective cohorts, there is evidence of the potential protective and therapeutic roles of vitamin C, D, zinc, and selenium in COVID-19. The findings summarized in this review will contribute to guide interventions in clinical practice or in future clinical studies. enhancing the differentiation and proliferation of B-and T-cells. Also, vitamin C has antiinflammatory effects such as inhibition of nuclear factor kappa B (NF-κB) and reducing pro-inflammatory mediators, as well as antioxidant activities, fighting free radicals and regenerating other antioxidants [18, 19] . Supplementation with vitamin C appears to have preventive and treatment capabilities against respiratory and systemic infections, improving several functions of immunological cells. These findings are still controversial and further high quality studies need to be completed in order to confirm the results. Vitamin C deficiency has been reported in respiratory infections, leading to impaired immunity and increasing susceptibility to infections. In turn, infections can significantly impact vitamin C level due to enhanced inflammation and metabolic requirements [11, 18, 20, 21] . The therapeutic use of vitamin C may be reasonable for pneumonia patients who have low vitamin C plasma levels [20] . Vitamin C also has pleiotropic physiological functions relevant to COVID-19 ( Figure 1 ), including prevention of microthrombi formation and capillary plugging, reduction of inflammatory markers elevation (cytokine storm), reduction of oxidative stress and has been suggested as having a role in antiviral cytokine interferon levels [10] . Some studies have examined the effects of vitamin C on primary and secondary outcomes of COVID-19 patients (Supporting information Table S2 ). Studies addressing previous vitamin C status and COVID-19 were not found in our search. Despite this, low intake levels of vitamin C have adverse effects on the incidence and severity of infections [22] . Vitamin C deficiency may be associated with risk of respiratory disease incidence. A European cohort study found that high plasma J o u r n a l P r e -p r o o f vitamin C concentrations at baseline were significantly associated with the lower incidence of respiratory illness, chronic respiratory diseases and pneumonia [23] . A pilot study measured serum vitamin C levels in a cohort of patients with critical COVID-19 illness in a hospital intensive care unit (ICU). The authors found low serum COVID-19 patients were treated with dexamethasone and vitamin C had a high recovery rate (94%) and low levels of serum ferritin. The authors suggest vitamin C and dexamethasone as key modalities for COVID-19 treatment. However, it is not safe to assert that vitamin C had a role in the recovery rate due to the absence of a comparator or a control group. Furthermore, the used dosage of vitamin C is not clear [26] . Other observational studies with hospitalized COVID-19 patients who received A pilot trial conducted by Zhang et al. (2021) [34] tested whether HDIVC was effective for severe COVID-19. The intervention group received 12 g of HDIVC every 12 h for 7 days. There was no difference in invasive mechanical ventilation-free days in 28 days between two groups (26.0 [9.0 -28.0] in HDIVC vs 22.0 [8.50 -28 .0] in control, (p = 0.57). HDIVC did not reduce 28-day mortality (p = 0.27). During the treatment period, patients in the HDIVC group had a steady rise in PaO2/FiO2, not observed in the control group. IL-6 levels in the HDIVC group were lower than that in the control group on day 7. However, some limitations were reported, among these, sample size, time for initiating vitamin C treatment, lack of viral load measurement, and the imbalance in the patient gender distribution between the groups at baseline. In an open-label randomized controlled trial conducted in Pakistan, the intervention group received 50 mg/ kg/ day of intravenous vitamin C along with the standard therapy. COVID-19 patients who received intravenous vitamin C became symptom-free earlier (7.1 ± 1.8 vs. 9.6 ± 2.1 days, p <0.0001) and spent fewer days in the hospital (8.1 ± 1.8 vs. 10.7 ± 2.2 days, p <0.0001) compared to those who received standard therapy only. However, Vitamin C supplementation had no impact on mortality and the need for mechanical ventilation [35] . Other clinical trials have not found the same result. Siahkali et al. (2021) [36] did not observe significantly better outcomes such mortality, duration of hospitalization and need for ICU admission, with HDIVC treatment (6g/ day for 5 days). Similar work by hormone, can exert immunomodulatory activities through functional cell steroid receptors [42, 43] . The many levels of defense involved in the role of vitamin D in the immune system were summarized by Schwalfenberg (2011) [44] . The first level is the physical barrier of epithelial cells in the skin, gut, and respiratory system, which protects us from injury or invasion by infection. The mechanisms of this action can be explained by 1,25(OH)D2 upregulating genes via the 1a-hydroxylase enzyme, which then encodes proteins required for tight junctions, gap junctions and adherens junctions [45, 46] . Secondly, vitamin D stimulates the production and secretion of antimicrobial peptides by the intestinal epithelial cells, Paneth cells, and intraepithelial lymphocytes in innate immunity [47] . Thirdly, 1,25(OH)2D exerts a receptor-mediated effect on monocyte function that results in increased oxidative burst potential [48] . Moreover, vitamin D modulates T helper (Th) cell responses in inducing a shift from Th1 to Th2 and preventing cytokine storms by decreasing inflammatory cytokines and NF-κB [7] . Within the innate immune response vitamin D can promote autophagy to facilitate viral clearance indirectly. This crucial role is important for maintaining appropriate balance between autophagy and apoptosis to maximize antiviral responses to infection [49] (Figure 1 ). Several concordant studies support a protective role for vitamin D in reducing at least the risk/severity of acute respiratory tract infection (ARI) [50 -52] . It is known that vitamin D/VDR signaling plays an important role in alleviating lipopolysaccharideinduced acute lung injury by preserving alveolar barrier integrity [53] . A study reported that children aged less than 2 years requiring hospitalization for ARI had significantly higher odds (1.7-times) of vitamin D deficiency when compared to those with mild ARI [51] . A prospective cohort study developed during 114 days of the fall and winter, which included healthy adults, showed a two-fold reduction in the risk of developing (ARI) in those with serum 25(OH)D levels of 38 ng/mL (95 nmol/L) or higher [50] . In this sense, J o u r n a l P r e -p r o o f 13 meta-analyses of randomized controlled trials conducted including data from 46,331 participants in 42 randomized controlled trials, stratified by baseline 25(OH)D concentration, reveal protective effects of vitamin D against ARI, although these effects were of modest size [54] . After the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we have observed a burst of scientific publications speculating on the mechanisms of infection that determine the relationship between COVID-19 and vitamin D status [5, 8, 43, 49, 55] . In fact, this infectious disease causes ARDS and acute lung injury leading to pulmonary cytokine storm, a major cause of morbidity and mortality. Overall, vitamin D influences lung structures, size, volume, and functions. The importance of ACE2 receptors in the pathophysiology of COVID-19 has been the most discussed point in this topic. ACE2 is known to be expressed in type II pneumocytes. SARS CoV-2 activates ubiquitously expressed ACE-2 receptors on the cell surface and can subsequently ingress into the cell. Vitamin D may downregulate the ACE2 expression and prevent the viral entry into cells. Apart from the immunomodulatory and anti-viral effects, 1,25(OH)2D acts specifically as a modulator of the renin-angiotensin pathway and down-regulates ACE2 expression, which serves as the host cell receptor that mediates infection by SARS-CoV-2. This class of receptors also inhibits transcription factors important in the regulation of the genetic expression of renin, which is another mechanism for conjecture of protection in the course of the disease [43, 49] . The reports selected from this topic came from prospective and retrospective cohort, case controls, and clinical trial studies described in Supporting Information Table S3 . A retrospective cohort included 4314 patients tested for COVID-19, all of whom had a vitamin D level checked in the year before testing. Predicted COVID-19 rates in J o u r n a l P r e -p r o o f the individuals with deficient vitamin D status were 21.6% vs 12.2% in the sufficient individuals. Testing positive for COVID-19 was also associated with increasing age, up to 50 years old (relative risk, 1.06; 95% CI, 1.01 -1.09; p = 0.02); non-White race (relative risk, 2.54; 95% CI, 1.26 -5.12; p = 0.009), and likely deficient vitamin D status (relative risk, 1.77; 95% CI, 1.12 -2.81; p = 0.02) compared with likely sufficient vitamin D status. These findings were not associated with comorbidities except for a decreased risk in persons with conditions associated with immunosuppression (Relative risk (RR), 0.39; 95% CI, 0.20 -0.76; p = 0.005) [56] . Analyzing records of patients from Switzerland, 107 symptomatic individuals obtaining a SARS-CoV-2 PCR test found that PCR-positive patients had significantly lower (p = 0.004) 25(OH)D (11.1 ng/mL) when compared with test-negative subjects (24.6 ng/mL). This was also confirmed by stratifying patients according to age >70 years [57] . In a sample of 780 hospitalized patients testing positive for COVID-19 in Indonesia, the odds ratio of death was higher in older and male cases with pre-existing conditions and below normal vitamin D levels. After controlling for age, sex, and comorbidity, both insufficient (OR = 7.63) and deficient 25(OH)D levels (OR = 10.12) were significantly associated with COVID-19 mortality (p < 0.001 for each) [58] . These similar findings were also observed in a large US cohort study (n = 191,779) where SARS-CoV-2 positivity was inversely associated with circulating 25(OH)D levels after adjusting for latitudes, races/ethnicities, both sexes, and age ranges. In a multivariable analysis with adjustment for ethnicity severe vitamin D deficiency was associated with an OR of 1.275 (p < 0.001) for COVID-19 infection [59] . The mean plasma vitamin D level previously checked in health professionals from Israel was significantly lower among those who tested positive than negative for COVID--20.78)]. In multivariate analyses that controlled for demographic variables, and psychiatric and somatic disorders, the adjusted odds ratio of COVID-19 infection low plasma 25(OH)D levels appears to be an independent risk factor for COVID-19 infection and hospitalization. Age over 50 years was positively associated with the likelihood of hospitalization due to COVID-19 [60] . In 4510 UK Biobank participants tested for COVID-19 in a hospital setting, male gender, Black, Asian, and Minority ethnicity (BAME), higher BMI and greater household size were independently associated with significantly greater odds of COVID-19. In addition, greater risk of severe COVID-19 in BAME populations was not adequately explained by variations in cardiometabolic factors, 25(OH)-vitamin D levels or socioeconomic factors [61] . In contrast, the findings of Hastie, Pell and Sattar (2021) [ [63] . Second, a prospective study restricted to J o u r n a l P r e -p r o o f participants (n = 8297) who had records of COVID-19 test results from 22 assessment centers (between 16 March 2020 and 29 June 2020) reported that habitual use of vitamin D supplements was associated with a lower risk of COVID-19 infection, independent of lifestyle, socio-economic status, prevalent chronic diseases, and circulating vitamin D levels [64] . Retrospectively, the association of vitamin D levels was measured within 6 months before the COVID-19 test with the incidence of COVID-19 positivity, radiological findings, and laboratory parameters. In COVID-19 (227) and non-COVID-19 patients (260) the severe vitamin D deficiency (<10 ng/mL) was considerably more common in COVID-19 patients (44%) than in non-COVID-19 patients (31%). Among COVID-19-positive patients, the group with vitamin D levels of >30 ng/mL had significantly lower D-dimer and C-reactive protein (CRP) levels and a lower number of affected lung segments and shorter hospital stays [65] . Likewise, other authors noted positive findings of vitamin D levels of >30 ng/mL in hospitalized COVID-19 patients [66, 67] . [67] in respect of lower in-hospital mortality and need for invasive mechanical ventilation. These results support the potential benefit of raising serum level of serum 25(OH)D to at least 30 ng/mL to reduce the risk of morbidity and mortality of COVID-19. Contradictorily, low vitamin D level before and during the J o u r n a l P r e -p r o o f pandemic were not independently associated with SARS-CoV-2 seropositivity in a large cohort of working-age adults [68] . Exploring comorbidities, a multi-center, case-control study performed with 220 adults from the Arab Gulf found that lower levels of 25(OH)D were also observed among SARS-CoV2 positive cases when compared to negative controls, and there was increased risk of COVID-19 for old age (> 60 years) [OR 6.2, 95% CI, 2 -18; (p = 0.001)] as well as having type 2 diabetes [OR 6.4, (95% CI, 3 -14) ; p < 0.001)] and low HDL cholesterol (HDL-c) [OR 6.1 (95% CI, 3 -14) ; p < 0.001)]. Interestingly, the study showed a significantly higher prevalence of vitamin C and D supplement use in the SARS-CoV-2 positive group during the pandemic (p < 0.001). This probably occurred as a spontaneous preventive strategy from the individuals [69] . Most studies developed with COVID-19 hospitalized patients address vitamin D as a useful prognosticator in the scenario of COVID-19 because during treatment it is possible to evaluate risk factors associated with vitamin D status and the longer duration, severity, and mortality of the disease. In older patients aged ≥ 65 years COVID-19-positive arm demonstrated lower median serum 25(OH)D level of 27 nmol/L (IQR=20-47 nmol/L) compared with COVID-19-negative arm, with median level of 52 nmol/L (IQR=31.5-71.5 nmol/L) (p value=0.0008). Among patients with vitamin D deficiency, there was higher peak Ddimer level (p = 0.034) and higher incidence of non-invasive ventilation (NIV) support and high dependency unit (HDU) admission (30.77% vs 9.68%) (p = 0.042). However, older adults with vitamin D deficiency and COVID-19' may demonstrate worse morbidity outcomes [70] . Sulli et al. (2021) [71] also found vitamin D deficiency more frequent in elderly COVID-19 hospitalized patients (78% of patients) than in sex-and J o u r n a l P r e -p r o o f age-matched controls (57% of subjects). In addition, the study reported that vitamin D deficiency was associated with more severe lung involvement, longer disease duration, and risk of death in elderly COVID-19 patients. A pilot study on a Greek ICU Cohort showed that eighty (80%) percent of critically ill COVID-19 pneumonia patients had vitamin D deficiency. As well as this, those who died within 28 days appeared to have lower ICU admission 25(OH)D levels compared to survivors [72] . Another retrospective cohort trial in 186 cases of severe COVID-19 found that low 25(OH)D levels on hospital admission were associated with COVID-19 pneumonia radiologic stage and mortality. Vitamin D deficiency on hospital admission was associated with COVID-19 mortality with an odds ratio of 3.87, independent of age, chronic lung disease, coronary artery disease, hypertension, or diabetes [73] . Patients treated in Respiratory Intermediate Care Unit with acute respiratory failure due to COVID-19 and severe vitamin D deficiency, after 10 days of hospitalization, had 50% of mortality probability, while those with vitamin D ≥10 ng/mL had a 5% mortality risk (p = 0.019). This study provided preliminary evidence to demonstrate an association between vitamin D deficiency and COVID-19 disease incidence and severity [74] . Thereafter, vitamin D insufficiency (22.8%) and deficiency (69.1%) were present in patients of Turkey with severe-critical COVID-19. Serum 25(OH) vitamin D levels was an independent predictor of mortality (p = 0.010) [75] . Another study among 464 SARS-CoV-2-positive patients from the United Arab Emirates confirms the association of levels < 12 ng/mL with COVID-19 severity and mortality [76] . As well as this, authors described a subgroup analysis of an overall 205 COVID-19 patients with severe disease, resulting in more evidence of mortality rate in patients with A case-control study found that vitamin D-deficient severe/critical COVID-19 cases (41.9%) compared to healthy controls (11.1%) were significantly older and had higher percentages of comorbidity (renal failure). Also, vitamin D deficiency was the greatest in severe/critical cases (80%), compared with mild cases (36%) these associations remaining even after controlling for demographics and comorbidities. These Despite the lower values of 25(OH)D in COVID-19 patients, three additional studies did not find any significant association of vitamin D levels with mortality, the need for mechanical ventilation, ICU admission, [94] [95] [96] , and the development of thromboembolism in COVID-19 patients with a documented vitamin D level within the past 12 months [95] . A large observational study of hospital in-patients with COVID-19 was carried out on hospital in-patients with the most severe clinical manifestations of COVID-19. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy with a high-dose of cholecalciferol (20,000 to 50,000 weekly). This intervention, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19 [97] . As well as this, a descriptive study noted that COVID-19 patients who had received a high dose of vitamin D supplementation achieved normalization of vitamin D levels and improved clinical recovery evidenced by shorter lengths of stay, lower oxygen requirements, and a reduction in inflammatory marker status [98] . dehydrogenase (LDH) and Neutrophil/Lymphocyte (N/L)], between the two groups was highly significant (p < 0.01) with the reduction in VD group being markedly higher than the NVD group. Improvement of serum 25(OH)D level to 80-100 ng/mL significantly reduced the inflammatory markers without any side effects [99] . A study including patients (aged 74 ± 13 years) with COVID-19 provides supplementation (or not) with 400,000 IU (as bolus oral cholecalciferol administered on two consecutive days). Patients were followed up during their in-hospital stay for an average time of 14 ± 10 days. For analysis, a composite outcome, including the need for transfer to ICU (for invasive mechanical ventilation) and/or death from any cause, was considered. Twenty-seven (29.7%) patients were transferred to the ICU and 22 (24.2%) patients died, six cases after being transferred to the ICU (and 16 cases prior to transfer to ICU). Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU or death. In a crude analysis, initially including comorbidity burden as a potential confounder, vitamin D treatment was observed to be associated with a 43% and 55% reduction, respectively, in the odds ratio of the combined endpoint, but these effects did not reach statistical significance [100] . Agreeing with these findings, in a quasi-experimental study, authors noted that irrespective of all measured potential confounders, regular bolus vitamin D3 supplementation (50,000 IU vitamin D3 per month, or doses of 80,000 IU or 100,000 IU vitamin D3 every 2-3 months) was associated with less severe COVID-19 and better survival rate in frail hospitalized elderly from a French nursing-home [101] . A retrospective, multicenter, open, non-randomized cohort study reported that patients supplemented with calcifediol (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) had lower risk of death during hospitalization during the first 30 days (5% vs. 20%, p-value < 0.01) compared to patients not receiving such treatment [102] . In contrast, treatment with oral cholecalciferol (median dose of 60,000 IU) did not make any difference to the outcomes in hospitalized COVID-19 patients [103] , and this includes the intervention of 800 IU/mo of 25(OH)D supplements used in another study [104] . During a pilot randomized clinical study, patients hospitalized with COVID-19 infection were treated with oral calcifediol (25OHD3), 0.532 mg on day 3 and 7, which continued weekly until discharge or ICU admission. All hospitalized patients received to determine the differences in recovery times of symptoms and revealed that the number of days to resolve cough was significantly shorter in the 5000 IU group than the 1000 IU group (6.2 ± 0.8 versus 9.1 ± 0.8; unadjusted p = 0.007). The same shorter period was observed for ageusia (loss of taste), again in favor of the 5000 IU group (11.4 ± 1.0 versus 16.9 ± 1.7; unadjusted p = 0.035). The significance for cough decreased but persisted even after adjusting for age, sex, baseline BMI, and D-dimer (p = 0.039), while the same significance was observed for ageusia (p = 0.035). The authors suggested the use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status. A Brazilian multicenter, double-blind, parallel-group trial that was randomized and placebo-controlled was performed using a single high dose of vitamin D3 among hospitalized patients with moderate to severe COVID-19, testing as primary outcome the response on hospital length of stay (defined as the total number of days that patients remained hospitalized from the date of randomization until the date of hospital discharge). The secondary outcomes were mortality during hospitalization, admission to the ICU; The median (IQR) hospital length of stay was not significantly different between the vitamin D3 (p = 0.94). Moreover, a post hoc analysis showed no changes in the median length of stay between groups. There were no significant differences between the vitamin D3 and placebo groups regarding secondary outcomes [108] . In conclusion, a single high Zinc deficiency is a common condition and a public health problem in almost all low-and middle-income countries [109] . Zinc is involved in numerous processes such as DNA synthesis, RNA transcription, gene expression, cell division, cell proliferation, apoptosis, immune response, intracellular signaling, growth, sense of smell and taste, and appetite [110 -112] . Zinc affects both innate and adaptive immunity. Its role in the immune system has been reviewed elsewhere [113] [114] [115] . Briefly, zinc is essential for the normal development and function of innate immune cells, such as neutrophils and natural killer (NK) cells [113] . Zinc deficiency negatively influences phagocytosis and chemotaxis of neutrophils and it impairs the recognition of major histocompatibility complex class I in target cells as well as the cytotoxic and lytic activity of NK cells [114] . In addition, altered zinc homeostasis in macrophages causes impaired phagocytosis and leads to an abnormal inflammatory response [116] . Regarding the adaptive immune response, zinc is also important for the growth and function of T and B cells. As reviewed before [113] , zinc deficiency is associated with thymic atrophy, lymphopenia, compromised cell-and antibody-mediated responses, and increased risk of infections. Moreover, zinc deficiency decreases the production of IFN-γ which leads to immune dysfunction mediated by the imbalance between lymphocytes Th1 and Th2. Additionally, zinc deficiency leads to increased production of inflammatory cytokines (TNF-α, IL-1b) by macrophages and activated monocytes which contribute to increased production of ROS, a byproduct of inflammation. This inflammatory and oxidative profile activates NFκB pathways aggravating this profile. These immune responses consist of a coordinated action of specialized cells, communicating with molecules and functional responses [9] . In this context, zinc finger proteins, zinc transporters and zinc homeostasis are essential to ensure proper signaling pathways and networks of the immune response through several mechanisms which are discussed elsewhere [114, 117] . However, zinc deficiency as well as zinc excess lead to malfunction of the immune system and its homeostasis is crucial to proper immune responses avoiding overreaction and cytokine storms [114] . mucociliary clearance; and (6) zinc increases the IFN-α production by leukocytes and potentiates its antiviral activity (Figure 1 ). No cohort study addressing previous zinc status and risk of COVID-19 was identified in our search. However, zinc deficiency has been associated with the prevalence of other respiratory tract infections [13] . In regard to our search, 10 observational studies aimed to investigate the effect of zinc status in patients with COVID-19 [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] . All of them observed adults and elderly patients, including pregnant women in one study [123] (Supporting information Table S4 ). In a case-control study, Elham et al. (2021) [118] found that COVID-19 hospitalized patients had lower serum zinc levels compared to healthy individuals. Possibly the nutritional supply of zinc contributed to maintaining a favorable zinc status and improving the antioxidative defense, energy metabolism, and immune response. These authors found that zinc associated with selenoprotein P (SELENOP) status within the reference ranges is a reliable indicator of survival in COVID-19 and a personalized supplementation of these micronutrients may support convalescence. In another study, hypozincemia (serum zinc < 70 mg/dL) was associated with COVID-19 severity in hospitalized patients. The authors suggest the use of serum zinc as a predictive clinical parameter for a critical illness of COVID-19 and to incorporate this measurement as one of the routine blood tests to focus on adequate zinc supply in ICU. They observed that an adequate enteral nutrition support for 10-12 days can recover the serum zinc levels to the normal range in critically ill patients [121] . Jothimani et al. (2020) [122] conducted a comparative analysis between COVID-19 patients and healthy volunteers and aimed to verify the correlation between serum zinc levels in patients with COVID-19 and the disease severity. COVID-19 patients were zinc deficient (serum zinc < 80mg/dL) compared to healthy adults. Moreover, low baseline zinc levels were associated with higher complication rate, increased tendency to develop ARDS, longer hospital stays, and increased mortality. Other studies demonstrated a correlation between serum zinc levels and COVID-19 outcome. Low serum zinc levels (50 μg/dL at admission) were correlated with worse clinical presentation, longer time to reach stability, and higher mortality of hospitalized patients [124] . In critically ill patients with COVID-19, low serum zinc levels (< 70 J o u r n a l P r e -p r o o f µg/dL) were extremely prevalent at admission to the ICU and were associated with a degree of organ failure manifested with severe ARDS [125] . Skalny et al. (2021) [126] aimed to investigate the association of metal profile with markers of lung damage. These authors found that zinc and other metals (calcium, iron, and selenium) gradually decrease as the COVID-19 severity increases. These metal levels correlated positively with SpO2 and were inversely associated with fever, lung damage, and CRP concentrations. In an investigation into multiple nutritional parameters in patients admitted with COVID-19, nutritional risk was associated with COVID-19 severity. In addition, severe patients showed lower serum zinc levels compared with non-severe patients. These authors point to the importance of developing international guidelines to advise on regular nutritional screening and nutritional support in COVID-19 [127] . In regard to our search, 3 retrospective observational studies aimed to investigate the effect of zinc supplementation in adults or elderly patients with COVID-19 [128] [129] [130] (Supporting information Table S4 ). A retrospective study showed that zinc supplementation in addition to the standard care (hydroxychloroquine and azithromycin) increased the frequency of patients being discharged from the hospital and decreased the need for ventilation and admission to the ICU. Also, zinc supplementation was associated with decreased transition to hospice for patients that did not require intensive care. These authors suggest a synergistic mechanism of zinc and hydroxychloroquine in preventing the virus from progressing, however, the effectiveness of zinc may reduce in severe cases marked by intense oxidative and inflammatory profiles. In this sense, viral RNA levels in clinical specimens of patients with COVID-19 should be investigated before and after zinc supplementation [128] . According to our search, 3 They also observed that a high dose of venous zinc administration (0.24 mg/kg/day of elemental zinc for a maximum of 7 days) was safe and able to increase serum zinc levels above the zinc deficiency cutoff adopted (10.7 μmol/L). Selenium (Se) is an essential trace element of high importance for human health and particularly for a well-balanced immune response. Selenium is found in foods and nutritional supplements in organic (selenomethionine, selenocysteine, selenium- for peripheral tissues also performing extracellular antioxidant function [12, 133] . Thus, selenium plays a role in antioxidant, anticarcinogenic, anti-inflammatory, redox and immune-cell function as well as in the regulation of thyroid hormone metabolism. Studies have already identified associations between selenium deficiency and increased morbidity and mortality from viral infections, cardiovascular, and thyroid diseases, as well as prostate, gastrointestinal, and breast cancers [14, 133, 134] . Evidently, it is well established that selenium is useful for the competency of the cellular component of both innate and adaptive immunity [12, [135] [136] [137] [138] . As the first line of defense, innate immune cells possess immediate protective mechanisms including antimicrobial enzymes and peptides, which can target various pathogens for lysis or phagocytosis by phagocytic cells. In addition, in the cascade of reactions to infection, the inflammatory response is triggered by the production of chemical mediators, enzymes and cytokines induced by molecular mechanisms associated with pathogens [139] . On a cellular level, selenium status may influence various leukocytic functions including adherence, migration, phagocytosis, and cytokine secretion. In this context, selenoproteins also regulate or are regulated by cellular redox tone, which is a crucial modulator of immune cell signaling [12] . However, for several reasons, selenium/selenoproteins are relevant in the viral pathogenicity, notably reducing proliferation of T cells, lymphocyte-mediated toxicity and NK cell activity, all of which are crucial for antiviral immunity [12, 136, 137] . Keshan disease was the first endemic cardiomyopathy from a virus related to selenium deficiency J o u r n a l P r e -p r o o f which had a reduced incidence in the face of selenium supplementation. Mechanisms related to low GPx-1 activity have been associated with the incidence of Keshan disease [140] . Selenium intervention has also shown benefits in the response to viral infections according to animal models of lethal influenza infection [141] . On the other hand, in selenium-deficient mice, the levels of macrophages and CD8+ and CD4+ T cells were lower compared to mice with adequate selenium levels, suggesting that selenium deficiency affects cellular immunity [142] . Other examples of the effects of selenium on viral pathogenicity have been demonstrated based on lower plasma selenium concentrations during early stages of HIV-1 [143] ; and due to adjuvant treatment of patients using high levels of selenium, there was reduced mortality rate in patients with severe sepsis or septic shock [144] . are involved in most of these functions. GPXs, TXNRDs and ER selenoproteins influence the viral pathogenicity, partly by reducing oxidative stress generated by viral pathogens [145] [146] [147] [148] (Figure 1) . What is more, prostacyclin (PGI2) regulation and the cyclooxygenase-2 (COX2) expression can be influenced by selenium status [139] . The with outcomes that indicate disease severity in COVID-19 [45, 149] . In summary, there is a mechanism proposed by Zhang et al. (2020) [14] by which selenium might suppress the life cycle and mutation to virulence of SARS-COV-2 while attenuating viral-induced oxidative stress, organ damage and the cytokine storm. Adding these findings, a current question has been posed speculating whether the disturbances induced by SARS-CoV-2 in the homeostasis of selenium contribute to the manifestation of COVID-19 coagulopathy [150] . In the outbreak of the pandemic of COVID-19 an ecological study pointed out the cure rate from COVID-19 associated with basal hair selenium concentration in different areas of China. Cured patients were those in whom temperature returned to normal for more than 3 days, respiratory symptoms were significantly improved, lung imaging showed significant reduction of inflammation, and there was negative nucleic acid test of respiratory pathogen on two consecutive occasions with a sampling interval of at least 1 day [151] . Collectively, the available studies support the belief that selenium may be of relevance in the infection with SARS-CoV-2 and disease course of 120, [152] [153] [154] . In the scope of this review, we found only 5 articles (all observational) aimed to evaluate the selenium status in patients with COVID-19 (Supporting information Table S5 ). The mortality risk was tested in 33 COVID-19 patients associated with total serum selenium total and selenoprotein P (SELENOP) compared with reference data from a This review encompasses scientific studies published during the past 16 months of the COVID-19 pandemic and provides an overview focused on the impact of micronutrient status in the face of this outbreak. In addition to summarizing relevant results, we expose substantial clinical and methodological heterogeneity across these studies. Worse clinical outcomes observed in patients with COVID-19 which have been associated with nutritional risk of vitamin C, vitamin D, zinc, and selenium deficiency are summarized in Figure 2 . Among 85 selected studies, only 11 RCTs were completed addressing interventions with vitamin C, vitamin D, zinc, and none for selenium. ( Table 6 ). In the set of observational studies, some confounding factors are related to the lack of knowledge on the nutritional status previous to the infection. For example, in the context of an inflammatory state, several mechanisms could be responsible for a decrease of serum 25(OH)D and plasma zinc, resulting in speculation that these events might be the cause or the consequence of inflammatory diseases [155] [156] . Thus, the measurements of most micronutrient biomarkers during the acute-phase response should be evaluated with caution, taking into consideration a possible reverse causality. Vitamin C levels were undetectable (detection limit 1.5 mg/L) in more than 90% of patients with COVID-19-associated ARDS in a study which was not in the scope of this review [157] . It seems reasonable to accept the prophylactic use of vitamin C in the COVID-19 context in some risk groups and regions of the world, given the favorable safety profile and low cost of vitamin C [11] . However, for the general population the current evidence for this recommendation is weak according to a previous review [20] . Overall, therapeutic doses of vitamin C used in randomized clinical trials varied on average from 50 mg/ kg/ day to 24 g/ day (Table 6) Most studies explored in our review supported that vitamin D deficiency impacts on COVID-19 hospitalization, severity, and mortality (Table S4) . As well as this, we have also reported on studies that showed no association between vitamin D status and COVID-19 clinical outcomes. In this context, the risk factors for developing severe COVID-19 are the same as those for developing vitamin D deficiency, so it is difficult to confirm if vitamin D deficiency itself is a risk factor for severe COVID-19 [158] . Viewed together, it is well accepted that the serum concentration of 25(OH)D is affected by a set of characteristics intrinsic to the individual in combination with environmental, socio-demographic, and lifestyle factors [159] . Furthermore, many observational studies do not perform the appropriate statistical analyses required to adjust data banks for potential confounders of low vitamin D, such as age, body mass index (BMI), and comorbidities. Well-designed observational studies are the best tools for planning clinical trials which require therapeutic evidence [160] . Apart from that, vitamin D deficiency can be plausibly linked to COVID-19. A meta-analysis conducted with observational studies found a positive association between vitamin D deficiency and the severity of the disease in a total sample of 8176 COVID-19 patients. Insufficiency of vitamin D concentration increased hospitalization (OR 1.81, 95% CI, 1.41 -2.21) and mortality from COVID-19 (OR 1.82, 95% CI, 1.06 2.58) [161] . Subsequently, in a systematic review and meta-analysis of 31 peer-reviewed observational studies, despite the mean 25(OH)D levels being 5.9 ng/mL lower in COVID-19 positive compared to negative patients, the certainty of the evidence was very low for a cause-effect relationship of vitamin D status and COVID-19 outcomes [162] . Recently, a live systematic review with evidence updated to March 11, 2021, which includes the studies cited here, did not find sufficient, good-quality evidence to assert whether vitamin D is an effective or safe treatment for adults with COVID-19 [158] . Based on such precedents, the exact efficacy of vitamin D supplementation for prevention of, or as an adjunct treatment for COVID-19 remains to be determined. The role of zinc in the immune system is well established. Due to its ubiquitous functions and influence on the immune response, zinc stands out as a promising therapeutic antiviral strategy against COVID-19. Despite the lack of clinical studies with greater samples, we found that zinc deficiency is common in patients with COVID-19 and it is related to poor outcomes. Some authors found low levels of serum zinc in COVID-19 patients compared to healthy individuals [119, 120, 123] . These low zinc levels may have originated from a previous deficiency or may have been caused or aggravated by the infection itself, since there is a competition for zinc between host and pathogens and zinc redistribution during J o u r n a l P r e -p r o o f inflammatory response [156] . However, evidence shows that low baseline zinc levels are associated with higher complication rates and poor outcomes, independent of its cause. What is more, zinc supplementation alone or in addition to standard care seems to bring positive results, especially in patients with zinc deficiency. Although authors have suggested a possible synergistic mechanism of zinc and hydroxychloroquine [129] , it is important to mention that this drug still lacks efficacy in COVID-19 and it could possibly be harmful [163] . Interestingly, risk factors for severe COVID-19 are also risk factors for zinc deficiency. Even with the strong homeostatic control, zinc status should be evaluated in patients and zinc supplementation should be considered as a preventive or supportive treatment for COVID-19. It is worth mentioning that zinc supplementation has positive effects without adverse side-effects. Obviously, more attention must be given to those patients with marginal or severe zinc deficiency. Several clinical trials with zinc and/or other drugs/dietary supplements for COVID-19 have been registered in ClinicalTrials.gov [164] . Soon, there will be more evidence to guide zinc interventions in COVID-19 management. Selenium intervention studies, although less frequent, have shown positive effects in terms of reducing the risk of totality, improving clinical parameters (e.g., OSCI score, transfer to ICU) and inflammation markers, increasing viral clearance and better survival during hospitalization in frail elderly individuals during COVID-19 [101] . The main findings of these studies indicated that low selenium and SELENOP concentrations were associated with survival and recovery rates of COVID-19 patients, and a novel composite biomarker (zinc status + SELENOP) has been tested as an indicator of survival in COVID-19 [120, 152, 153] . The fact that selenium and selenoprotein species have an J o u r n a l P r e -p r o o f active role in innate and adaptive immunity reinforces selenium as a nutritional tool to counteract viral infections. Particularly relevant to COVID-19, optimal nutritional status is fundamental to modulate inflammatory and oxidative stress processes. The immune system is constantly surveilling and when threatened is highly activated, which demands more energy and substrates (nutrients) from our diet. Nutrients and bioactive compounds from one's diet play key roles in supporting the human immune system. These substrates act synergically and their joint action surpasses the effect of one single nutrient [9] . For example, micronutrients support mucosal immune function (vitamin A), epithelial tissue integrity (vitamins A, C, and D), enhance the function of certain adaptive and innate immune cells (vitamins A, C, D, and E, iron, zinc, and PUFAs), and have potential pro-oxidant effects (vitamin C) [165] . A prospective, double-blinded, randomized parallel-controlled interventional clinical trial reported that anti-inflammatory antioxidant oral dietary supplementation significantly dampens the cytokine storm and leads to partial improvements in some clinical parameters among patients with non-critical COVID-19 [166] . As is already known, it is not possible to separate the effects of individual micronutrients in treatments comprising of combinations of various antioxidants [165] . Therefore, to achieve a healthy immunity it is imperative that individuals embrace a healthy lifestyle, which includes a diversified, balanced, and healthy diet, with sufficient amounts of essential nutrients. Achieving this will benefit the nutritional status and the immunological response against all sorts of pathogens, including COVID-19. As can be seen from the diversity of studies, deficiencies of vitamin C, vitamin D, zinc, and selenium can be considered a nutritional risk factor for patients with COVID-J o u r n a l P r e -p r o o f 19. Immunological dysfunctions observed in the pathogenicity of COVID-19 may be aggravated or attenuated, depending on the nutritional status of the host [167] . Another great challenge is understanding the underlying mechanisms of these micronutrients in the host against outbreaks and the individual ability to overcome infection by SARS-Cov-2. However, there is an extreme need for well-designed RCTs investigating the effectiveness of these micronutrient supplementations in individuals diagnosed with COVID-19. Certainly, this will produce additional scientific knowledge and evidence in order to apply better evidence-based practices in clinical strategies. LFCP, ANABB and LLL were responsible for conceiving the review. ANABB drew all the figures. All authors participated in analysis and interpretation of data and manuscript writing. All authors approved the final version of the manuscript before submission. The outbreak of COVID-19: An overview WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health? Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework The impact of nutrition on COVID-19 susceptibility and long-term consequences Micronutrients as immunomodulatory tools for COVID-19 management Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19 A Basic Review of the Preliminary Evidence That COVID-19 Risk and Severity Is Increased in Vitamin D Deficiency Nutrition, immunity and COVID-19 The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19 Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19 The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities Zinc and respiratory tract infections: Perspectives for COVID-19 Selenium and selenoproteins in viral infection with potential relevance to COVID-19 Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev The Pharmacokinetics of Vitamin C Vitamin C and Immune Function Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects Controversial Effects of Vitamin D and Related Genes on Viral Infections, Pathogenesis, and Treatment Outcomes Vitamin D: modulator of the immune system Could SARS-CoV-2-induced lung injury be attenuated by vitamin D? A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency Clinical and immunological features of severe and moderate coronavirus disease 2019 Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear vitamin D receptor Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation 1,25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes Mechanisms in endocrinology: Vitamin D and COVID-19 Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents Association of vitamin D deficiency with severity of acute respiratory infection: A case-control study in New Zealand children Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction -A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank Vitamin D and COVID-19 infection and mortality in UK Biobank COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19 Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study Vitamin D status and outcomes for hospitalised older patients with COVID-19 Lung Outcomes in Elderly COVID-19 Patients Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19 Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients Exploring the link between vitamin D and clinical outcomes in COVID-19 Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19 Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study) Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial Zinc deficiency in low-and middle-income countries: prevalence and approaches for mitigation Discovery of human zinc deficiency: its impact on human health and disease The Role of Zinc in Antiviral Immunity Zinc: a multipurpose trace element Zinc in human health: effect of zinc on immune cells Zinc as a Gatekeeper of Immune Function Zinc and immunity: An essential interrelation The Role of Zinc and Zinc Homeostasis in Macrophage Function Multiple impacts of zinc on immune function Serum vitamin D, calcium, and zinc levels in patients with COVID-19 Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19 Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker Analysis of the predictive factors for a critical illness of COVID-19 during treatment -relationship between serum zinc level and critical illness of COVID-19 COVID-19: Poor outcomes in patients with zinc deficiency The Relation Between Trace Element Status (Zinc, Copper, Magnesium) and Clinical Outcomes in COVID-19 Infection During Pregnancy Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2 Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Malnutrition: Percentage and Association with Prognosis in Patients Hospitalized for Coronavirus Disease Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19: An Observational Study Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients Selenium and human health Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio Role of selenium-containing proteins in T-cell and macrophage function Selenium, immune function, and resistance to viral infections The influence of selenium on immune responses Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols Selenium and selenoproteins in prostanoid metabolism and immunity Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy Protection from H1N1 influenza virus infections in mice by supplementation with selenium: a comparison with seleniumdeficient mice Selenium deficiency increases the pathology of an influenza virus infection Selenium status of HIV-1 infected individuals Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock Genetic variation in selenoprotein S influences inflammatory response Selenoproteins and Viral Infection The thioredoxin-1 system is essential for fueling DNA synthesis during T-cell metabolic reprogramming and proliferation Endoplasmic reticulum-resident selenoproteins as regulators of calcium signaling and homeostasis The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19 Impairment in selenocysteine synthesis as a candidate mechanism of inducible coagulopathy in COVID-19 patients Association between regional selenium status and reported outcome of COVID-19 cases in China An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status Selenium Deficiency Is Associated with Mortality Risk from COVID-19 Urinary trace elements in association with disease severity and outcome in patients with COVID-19 Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review Immunopharmacological perspective on zinc in SARS-CoV-2 infection Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev Biological Effects of Sunlight, Ultraviolet Radiation, Visible Light, Infrared Radiation and Vitamin D for Health Reassessing the Association of Vitamin D Level With SARS-CoV-2 Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials Zinc and COVID-19: Basis of Current Clinical Trials The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically Ill Patients: A Randomized Controlled Trial Host nutritional status: the neglected virulence factor The authors declare that they have no conflict of interest.